Navigation Links
QLT announces positive results from the evaluation of Visudyne(R) combination therapy
Date:6/2/2009

VANCOUVER, June 2 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced positive twelve-month primary analysis results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with wet age-related macular degeneration ("wet AMD"). The purpose of the study is to determine if Visudyne combined with Lucentis reduces retreatment rates compared with Lucentis monotherapy, while maintaining similar vision outcomes and an acceptable safety profile. Three Visudyne-Lucentis combination therapies were evaluated against Lucentis monotherapy. The overall results showed that fewer retreatment visits were required with the combination therapies than with Lucentis monotherapy, and the differences were statistically significant:

    1.  Triple therapy with quarter-fluence Visudyne followed by Lucentis and
        then dexamethsone (P=.04)
    2.  Triple therapy with half-fluence Visudyne followed by Lucentis and
        then dexamethsone (P less than .001)
    3.  Double therapy with half-fluence Visudyne followed by Lucentis
        (P=.04)

While the mean visual acuity (VA) may appear to have improved similarly across all treatment groups, the confidence intervals were wide. There were no unexpected safety findings, and adverse event incidence was similar across treatment groups.

Of the four treatment groups, the triple therapy half-fluence group demonstrated the best results, with the fewest retreatment visits and mean VA improvement most similar to Lucentis monotherapy through 12 months. Patients in the triple therapy half-fluence group had a mean of 3.0 retreatment visits compared with 5.4 for patients who received Lucentis monotherapy (P less than .001). At the month 12 examination, mean VA in the triple therapy half-fluence group imp
'/>"/>

SOURCE QLT Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Genoptix Announces Participation at the 29th Annual William Blair Growth Stock Conference
2. JLL Announces Extension of Its Offer to Acquire Patheon and Take Up of Deposited Restricted Voting Shares
3. Resource for Those Living with Hepatitis C Announces Website Redesign
4. Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder
5. Immucor Announces Fiscal Year 2010 Guidance
6. The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
7. ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
8. Michael J. Fox Foundation Announces Launch of PD Online Research
9. Roshan Announces Expansion of Afghanistans First Telemedicine Project to Bamyan Region
10. Endologix Announces Full Commercial Launch of IntuiTrak Express Delivery System
11. Cyberonics Announces Exclusive Distribution Agreement With Nihon Kohden in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce ... ever created for kids with cancer. The Chemo Duck App, available ... filled with enjoyable games to help children of all ages living ... helps to keep kids entertained, educated and at ease while waiting ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... 18, 2009 While video gaming is generally perceived as ... the average age of players in the United States is ... (CDC), Emory University and Andrews University analyzed survey data from ... in the Seattle-Tacoma area on health risks; media use behaviors ...
... , , , ... the U.S. have surpassed HMO plans in covered employees, according to ... 2009 UBA Health Pl a n Survey ... from 12,316 employers reporting. , , (Photo: ...
... INDIANAPOLIS, Aug. 17 Eli Lilly and Company (NYSE: ... Eastern District of Michigan has granted a motion by Sun Pharmaceuticals ... or method-of-use patent, for Gemzar((R)) (gemcitabine HCl for injection) which had ... on Gemzar,s compound patent, which remains valid until November 2010. , ...
... severe obstructive sleep apnea is associated with an increased ... especially men, according to new results from a landmark ... Institute (NHLBI) of the National Institutes of Health (NIH). ... date of a link between increased risk of death ...
... MIAMI, Aug. 17 In the recent Time Magazine ... Cloud tells us that these days, the more than 45 million Americans who ... "exercise, in other words, isn,t necessarily helping us lose weight. It may even ... Marta Montenegro is on a mission to tell Americans that these ...
... , , Scientific ... SAN FRANCISCO, Aug. 17 Scientists, physicians, consumers and environmental ... progress of their review of bisphenol A (BPA), a synthetic sex ... Henry Waxman and Bart Stupak asked for FDA to review their ...
Cached Medicine News:Health News:New study finds links between video-game playing and health risks in adults 2Health News:New study finds links between video-game playing and health risks in adults 3Health News:Consumer Driven Health Plans Surpass HMOs in Popularity With Employees 2Health News:Consumer Driven Health Plans Surpass HMOs in Popularity With Employees 3Health News:Consumer Driven Health Plans Surpass HMOs in Popularity With Employees 4Health News:Consumer Driven Health Plans Surpass HMOs in Popularity With Employees 5Health News:U.S. District Court Rules Against Lilly Regarding Gemzar Patent 2Health News:U.S. District Court Rules Against Lilly Regarding Gemzar Patent 3Health News:U.S. District Court Rules Against Lilly Regarding Gemzar Patent 4Health News:Severe sleep apnea tied to increased risk of death 2Health News:Editor-In-Chief of SOBeFiT Magazine, Marta Montenegro, Says Time Magazine's Article 'Why Exercise Won't Make You Thin' Sends the Wrong Message 2Health News:Editor-In-Chief of SOBeFiT Magazine, Marta Montenegro, Says Time Magazine's Article 'Why Exercise Won't Make You Thin' Sends the Wrong Message 3Health News:Editor-In-Chief of SOBeFiT Magazine, Marta Montenegro, Says Time Magazine's Article 'Why Exercise Won't Make You Thin' Sends the Wrong Message 4Health News:Toxic Chemical Threat: FDA Needs to Get BPA Out of Our Food 2
(Date:1/23/2015)... 2015 Gem Pharmaceuticals announced today that the initial ... the Company,s Phase 2 clinical trial.  This open-label study ... compound, GPX-150 (an investigational medication), in approximately 30 adults ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. ... that specializes in the development and sale of patented ... and active pharmaceutical ingredients (API) today announced the business ... API operation. 1. Following the September 2014 ...
(Date:1/22/2015)... 2015  BiOptix is pleased to announce the appointment of ... Chemistry and Biochemistry. Scott joins the company after previous scientific ... throughout the course of his nearly 20 year career ... a nationally recognized thought leader in the biosensor field ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: